announced yesterday theri competitors have serious efficacy...

announced yesterday theri competitors have serious efficacy issues with their drugs, that cxs dont have as far as i can tell, and with phase 2/3 underway and results to start filtering through in next couple of months with high likelihood of success, cxs SP should be much higher IMHO. When the penny drops, i think the market will clamour for stock at much higher SP levels...... huge revenues should flow for cxs from their Ceflatonin project.